Comparative Pharmacology
Head-to-head clinical analysis: CAMPATH versus KESIMPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAMPATH versus KESIMPTA.
CAMPATH vs KESIMPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alemtuzumab is a recombinant humanized monoclonal antibody that binds to CD52, a cell surface antigen expressed on B and T lymphocytes, NK cells, monocytes, and macrophages. Binding induces antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, resulting in prolonged lymphocyte depletion.
KESIMPTA (ofatumumab) is a fully human anti-CD20 monoclonal antibody that selectively binds to the CD20 antigen on B lymphocytes, leading to B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This results in depletion of circulating B cells, reducing inflammatory demyelination in multiple sclerosis.
12 mg/day intravenously over 2 hours, administered for 5 consecutive days (total 60 mg). For patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the recommended dose is 3 mg/day intravenously on day 1, 10 mg/day on day 2, and 30 mg/day on day 3 (dose escalation), followed by 30 mg/day three times per week on alternate days for up to 11 weeks (total cumulative dose up to 640 mg).
20 mg administered subcutaneously once monthly after a loading dose of 20 mg on Days 0, 7, and 14.
None Documented
None Documented
Terminal half-life approximately 12 days (range 6-21 days) after repeated doses, supporting weekly dosing in CLL.
16 days (range 13–20 days) with linear pharmacokinetics; supports every 4-week dosing.
Clearance via opsonization and degradation in reticuloendothelial system; negligible renal or biliary excretion (<1% unchanged).
Primarily degraded into small peptides and amino acids; not excreted renally or fecally as intact drug. Elimination pathways not fully characterized due to monoclonal antibody catabolism.
Category C
Category C
Monoclonal Antibody, Antineoplastic
Monoclonal Antibody, Anti-CD20